Bone density in children treated with gonadotropin-releasing hormone analogs for central precocious puberty
| Autor: | Maria Chiara Gallo, Franco Antoniazzi, Luciano Tatò, Rossella Gaudino, Sara Dal Corso, Marco Zaffanello, Paolo Cavarzere, Dario Zanon, Silvia Perlini, Elena Monti, Milena Brugnara, Evelina Maines |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Bone mineral
Peak bone mass medicine.medical_specialty Bone density medicine.diagnostic_test business.industry Endocrinology Diabetes and Metabolism Hypoestrogenism central precocious puberty Gonadotropin-releasing hormone GnRH analogs medicine.disease Endocrinology Internal medicine medicine Precocious puberty business bone mineral density Dual-energy X-ray absorptiometry Hormone |
| Popis: | Estrogens, growth hormones and IGFs are essential in the development and growth of the skeleton and for the maintenance of bone mass and density. Treatment of precocious puberty with gonadotropin-releasing hormone analogs (GnRHa), leads to a situation of hypoestrogenism by reducing sex-steroid levels, which, theoretically, may have a detrimental effect on bone mass during pubertal development. A reduction in bone mineral density during GnRHa treatment has been shown, but GnRHa treatment in patients with central precocious puberty does not seem to impair the achievement of normal peak bone mass at adult height. However, calcium supplementation is effective in improving bone densitometric levels and may promote better peak bone mass achievement. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|